Patents Assigned to AGIOS PHARMACEUTICALS, INC
  • Compounds and their methods of use
    Patent number: 10000479
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 19, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Rene M. Lemieux, Sheldon Cao, Yue Ding, Zhixiong Ye
  • Pyruvate kinase activators for use in therapy
    Patent number: 9980961
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 29, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Shin-San Michael Su, Lenny Dang
  • Method for treating cell proliferation related disorders
    Patent number: 9982309
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: May 29, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Leonard Luan C. Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • Pharmaceutical compositions of therapeutically active compounds
    Patent number: 9968595
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: May 15, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventor: Chong-Hui Gu
  • Therapeutic compositions and related methods of use
    Patent number: 9938259
    Abstract: Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 10, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders
  • Therapeutically active compounds and their methods of use
    Patent number: 9889137
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 13, 2018
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Samuel V. Agresta
  • Therapeutically active compositions and their methods of use
    Patent number: 9856279
    Abstract: Provided are piperazine compounds of Formula I useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 2, 2018
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy M. Travins, Shunqi Yan, Zhixiong Ye
  • Therapeutically active compositions and their methods of use
    Patent number: 9850277
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: December 26, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
    Publication number: 20170325708
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 16, 2017
    Applicant: Agios Pharmaceuticals, Inc.
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun G. Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • Therapeutically active compounds and their methods of use
    Patent number: 9751863
    Abstract: Provided are compounds useful for treating cancer and methods of making the compounds and intermediates described herein.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: September 5, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Shijie Zhang
  • Therapeutically active compounds and their methods of use
    Patent number: 9738625
    Abstract: Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 22, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Samuel V. Agresta, Chong-Hui Gu, David Schenkein, Hua Yang, Liting Guo, Zhen Tang, Jianming Wang, Yanfeng Zhang, Yan Zhou
  • Therapeutically active compounds and their methods of use
    Patent number: 9732062
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: August 15, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
    Patent number: 9724350
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 8, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jeremy Travins, Luke Utley
  • Therapeutically active compounds and their methods of use
    Patent number: 9694013
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: July 4, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Samuel V. Agresta
  • Pyruvate kinase activators for use in therapy
    Patent number: 9682080
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: June 20, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San Michael Su
  • Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer
    Patent number: 9662327
    Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 30, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
  • Therapeutically active compounds and their methods of use
    Patent number: 9656999
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 23, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
    Patent number: 9657004
    Abstract: Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: May 23, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders
  • COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20170137414
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Application
    Filed: March 20, 2015
    Publication date: May 18, 2017
    Applicant: AGIOS Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Rene M. Lemieux, Sheldon Cao, Yue Ding, Zhixiong Ye
  • Methods of evaluating patients using E-cadherin and vimentin
    Patent number: 9618514
    Abstract: Methods for the selection, evaluation, and/or treatment of a patient having cancer with an inhibitor of a glutamine-utilizing enzyme or a glutamine-depleting agent, by evaluating E-cadherin or vimentin expression are disclosed.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: April 11, 2017
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventors: Sung Eun Choe, Jonathan Hurov, Danielle Ulanet